Specificity and Promiscuity in Phosphoinositide Binding by Pleckstrin Homology Domains*

Abstract

Pleckstrin homology (PH) domains are small protein modules involved in recruitment of signaling molecules to cellular membranes, in some cases by binding specific phosphoinositides. We describe use of a convenient “dot-blot” approach to screen 10 different PH domains for those that recognize particular phosphoinositides. Each PH domain bound phosphoinositides in the assay, but only two (from phospholipase C-δ1and Grp1) showed clear specificity for a single species. Using soluble inositol phosphates, we show that the Grp1 PH domain (originally cloned on the basis of its phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) binding) binds specifically tod-myo-inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) (the PtdIns(3,4,5)P3headgroup) with K D = 27.3 nm, but bindsd-myo-inositol 1,3,4-trisphosphate (Ins(1,3,4)P3) or d-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) over 80-fold more weakly. We show that this specificity allows localization of the Grp1 PH domain to the plasma membrane of mammalian cells only when phosphatidylinositol 3-kinase (PI 3-K) is activated. The presence of three adjacent equatorial phosphate groups was critical for inositol phosphate binding by the Grp1 PH domain. By contrast, another PH domain capable of PI 3-K-dependent membrane recruitment (encoded by EST684797) does not distinguish Ins(1,3,4)P3 from Ins(1,3,4,5)P3 (binding both with very high affinity), despite selecting strongly against Ins(1,4,5)P3. The remaining PH domains tested appear significantly less specific for particular phosphoinositides. Together with data presented in the literature, our results suggest that many PH domains bind similarly to multiple phosphoinositides (and in some cases phosphatidylserine), and are likely to be regulated in vivo by the most abundant species to which they bind. Thus, using the same simple approach to study several PH domains simultaneously, our studies suggest that highly specific phosphoinositide binding is a characteristic of relatively few cases.

Footnotes

  • * This work was supported in part by National Institutes of Health Grant DK49207 (to E. Y. S.), Telethon Italy Grant 328/bi (to M. F.), an award from the McCabe Fund of the University of Pennsylvania (to M. A. L.), and Damon Runyon Scholar Award DRS-05 from the Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation (to M. A. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • § These two authors contributed equally to this study.

  • ** To whom correspondence should be addressed: Dept. of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, A606 Richards Bldg., 3700 Hamilton Walk, Philadelphia, PA 19104-6089. Tel.: 215-898-3072; Fax: 215-573-4764; E-mail: mlemmon{at}mail.med.upenn.edu.

  • Abbreviations:
    PH

    pleckstrin homology

    PtdIns(4

    5)P2, phosphatidylinositol 4,5-bisphosphate

    PtdIns(3

    4,5)P2, phosphatidylinositol 3,4,5-trisphosphate

    PLC

    phospholipase

    PI 3-K

    phosphatidylinositol 3-kinase

    PKB

    protein kinase B

    Grp1

    general receptor for phosphoinositides-1

    Btk

    Bruton’s tyrosine kinase

    βARK

    β-adrenergic receptor kinase

    Sos

    Son-of-sevenless

    GST

    glutathioneS-transferase

    DTT

    dithiothreitol

    PBS

    phosphate-buffered saline

    TBS

    Tris-buffered saline

    SUV

    small unilamellar vesicle

    PtdCho

    phosphatidylcholine

    PtdSer

    phosphatidylserine

    PtdIns

    phosphatidylinositol

    PlecN-PH

    N-terminal PH domain from pleckstrin

    ITC

    isothermal titration calorimetry

    EGFP

    enhanced green fluorescent protein

    DAGK-δ

    diacylglycerol kinase-δ

    IP4BP

    inositol 1,3,4,5-tetrakisphosphate-binding protein

    ARF

    ADP-ribosylation factor

    MOPS

    4-morpholinepropanesulfonic acid

    Ins(1

    3,4)P3, d-myo-inositol 1,3,4-trisphosphate

    Ins(1

    4,5)P3,d-myo-inositol 1,4,5-trisphosphate

    Ins(1

    5,6)P3, d-myo-inositol 1,5,6-trisphosphate

    Ins(1

    4,5,6)P4,d-myoinositol 1,4,5,6-tetrakisphosphate

    Ins(3

    4,5,6)P4, d-myo-inositol 3,4,5,6-tetrakisphosphate

    Ins(1

    3,4,5)P4,d-myo-inositol 1,3,4,5-tetrakisphosphate

    Ins(1

    2,5,6)P4, d-myo-inositol 1,2,5,6-tetrakisphosphate

    Ins(1

    3,4,6)P4,myo-inositol 1,3,4,6-tetrakisphosphate

    Ins(1

    3,4,5,6)P5, myo-inositol 1,3,4,5,6-pentakisphosphate

    PtdIns-3-P

    phosphatidylinositol 3-phosphate

    PtdIns-4-P

    phosphatidylinositol 4-phosphate

    PtdIns(3

    4)P2, phosphatidylinositol 3,4-bisphosphate

    InsP6

    myo-inositol hexaphosphate

    Ins(1

    2,6)P3, d-myo-inositol 1,2,6-trisphosphate

    Ins(3

    5,6)P3,d-myo-inositol 3,5,6-trisphosphate.

    • Received June 5, 1998.
    • Revision received September 2, 1998.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement